Secor Capital Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Secor Capital Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-69,003	Closed	-$1.58M	–	600
2018 Q3	$1.58M	Buy	69,003 +17,340	+34%	+$354K	0.17%	180
2018 Q2	$984K	Buy	51,663 +11,770	+30%	+$197K	0.08%	306
2018 Q1	$672K	Sell	39,893 -87,384	-69%	-$1.46M	0.06%	346
2017 Q4	$1.94M	Buy	127,277 +33,005	+35%	+$490K	0.08%	202
2017 Q3	$1.69M	Sell	94,272 -26,866	-22%	-$450K	0.16%	201
2017 Q2	$1.98M	Sell	121,138 -12,783	-10%	-$184K	0.18%	187
2017 Q1	$1.88M	Buy	133,921 +17,766	+15%	+$253K	0.21%	155
2016 Q4	$1.85M	Buy	116,155 +47,586	+69%	+$765K	0.23%	136
2016 Q3	$1.14M	Buy	+68,569	New	+$923K	0.12%	236

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Secor Capital Advisors's VNDA Position: Q4 2018 in Review

Secor Capital Advisors sold out of Vanda Pharmaceuticals (VNDA) in Q4 2018, closing a stake of 69,003 shares — an estimated $1.58M sold.

Secor Capital Advisors first reported a position in VNDA in Q3 2016 and held it in 9 quarters. The position peaked at $1.98M in Q2 2017. 186 funds tracked by Wall St. Rank hold VNDA as of Q4 2018.

Secor Capital Advisors reported no remaining Vanda Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Secor Capital Advisors sold 69,003 Vanda Pharmaceuticals shares in Q4 2018, an estimated $1.58M.
Secor Capital Advisors first reported a position in Vanda Pharmaceuticals in Q3 2016 and held it in 9 quarters.
Secor Capital Advisors's Vanda Pharmaceuticals position peaked at $1.98M in Q2 2017.
186 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2018.

Based on Secor Capital Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.